Carrick Therapeutics Limited

This study tested whether adding the drug samuraciclib to standard hormone therapy (fulvestrant) works better than fulvestrant alone for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The trial included 60 adults whose cancer had worsened despi…

This study tested a new two-drug combination (samuraciclib and elacestrant) in 49 adults with a specific type of advanced breast cancer (HR+/HER2-). The goal was to see if the combination is safe and can slow down the cancer's growth. Participants had already tried other treatmen…

This study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth, and the study looked at how it works in dif…